ABL Bio Inc (298380) - Total Liabilities

Latest as of June 2026: ₩99.78 Billion KRW ≈ $67.62 Million USD

Based on the latest financial reports, ABL Bio Inc (298380) has total liabilities worth ₩99.78 Billion KRW (≈ $67.62 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 298380 long-term investment intensity to see how much of total assets are deployed in long-term investments.

ABL Bio Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how ABL Bio Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of ABL Bio Inc.

ABL Bio Inc Competitors by Total Liabilities

The table below lists competitors of ABL Bio Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Ta Liang Technology Co Ltd TW:3167	Taiwan	NT$7.80 Billion
Axogen Inc NASDAQ:AXGN	USA	$44.68 Million
Werner Enterprises Inc NASDAQ:WERN	USA	$1.88 Billion
Pou Chen Corp TW:9904	Taiwan	NT$140.29 Billion
Northwest Bancshares Inc NASDAQ:NWBI	USA	$15.29 Billion
Suzhou TZTEK Technology Co Ltd SHG:688003	China	CN¥1.98 Billion
BW LPG Limited F:BW9	Germany	€1.23 Billion
Suzhou Hesheng Special Material Co Ltd SHE:002290	China	CN¥1.13 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down ABL Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 298380 net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.72	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.58	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.36	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ABL Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ABL Bio Inc (2016–2025)

The table below shows the annual total liabilities of ABL Bio Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩124.24 Billion ≈ $84.19 Million	+92.03%
2024-12-31	₩64.70 Billion ≈ $43.84 Million	-24.83%
2023-12-31	₩86.07 Billion ≈ $58.33 Million	-25.59%
2022-12-31	₩115.67 Billion ≈ $78.39 Million	+1117.57%
2021-12-31	₩9.50 Billion ≈ $6.44 Million	+2.93%
2020-12-31	₩9.23 Billion ≈ $6.25 Million	-15.28%
2019-12-31	₩10.89 Billion ≈ $7.38 Million	-8.50%
2018-12-31	₩11.91 Billion ≈ $8.07 Million	-88.80%
2017-12-31	₩106.32 Billion ≈ $72.05 Million	+441.66%
2016-12-31	₩19.63 Billion ≈ $13.30 Million	--

About ABL Bio Inc

KQ:298380 Korea Biotechnology

Market Cap

$2.25 Billion

₩3.32 Trillion KRW

Market Cap Rank

#5765 Global

#134 in Korea

Share Price

₩59300.00

Change (1 day)

-8.63%

52-Week Range

₩59300.00 - ₩245500.00

All Time High

₩245500.00